The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure
Open accessAbstract
Abstract Utilizing [18F]‐AV‐1451 tau positron emission tomography (PET) as an Alzheimer disease (AD) biomarker will require identification of brain regions that are most important in detecting elevated tau pathology in preclinical AD. Here, we utilized an unsupervised learning, data‐driven approach to identify brain regions whose tau PET is most informative in discriminating low and high levels of [18F]‐AV‐1451 binding. 84 cognitively normal participants who had undergone AV‐1451 PET imaging were used in a sparse k‐means clustering with resampling analysis to identify the regions most informative in dividing a cognitively normal population into high tau and low tau groups. The highest‐weighted FreeSurfer regions of interest (ROIs) separating these groups were the entorhinal cortex, amygdala, lateral occipital cortex, and inferior temporal cortex, and an average SUVR in these four ROIs was used as a summary metric for AV‐1451 uptake. We propose an AV‐1451 SUVR cut‐off of 1.25 to define high tau as described by imaging. This spatial distribution of tau PET is a more widespread pattern than that predicted by pathological staging schemes. Our data‐derived metric was validated first in this cognitively normal cohort by correlating with early measures of cognitive dysfunction, and with disease progression as measured by &bgr;‐amyloid PET imaging. We additionally validated this summary metric in a cohort of 13 Alzheimer disease patients, and showed that this measure correlates with cognitive dysfunction and &bgr;‐amyloid PET imaging in a diseased population. HighlightsAV‐1451 binding in four key regions identifies tau‐positive individuals with preclinical AD.The SUVR cutoff for high and low tau PET is 1.25.Increased tau PET correlates with early cognitive impairment, and relates to &bgr;‐amyloid burden in preclinical AD individuals.The spatial pattern of AV‐1451 uptake in preclinical AD is more widespread than predicted by pathological staging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationFischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 2×
“The amyloid cascade hypothesis proposes that the abnormal accumulation of β-amyloid is an early event that induces a cascade of changes that eventually results in tau pathology (neurofibrillary tangles, neuritic plaques and neuropil threads), synaptic and neuronal loss and, eventually, dementia (Hardy and Higgins, 199…”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · cited 1×
“…brain can be seen decades prior to symptom onset, both postmortem (Dela ere et al., 1989; Duyckaerts et al., 1987; McLean et al., 1999) and in vivo (Rowe et al., 2007; Villemagne et al., 2011) studies indicate that cross-sectional β-amyloid burden does not strongly correlate with concurrent…”
Background[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 2×
“However, there is precedent for establishing cutoffs, in Aβ PET imaging for example, within similarly sized or smaller cognitively normal cohorts (Cohen et al., 2013; Mintun et al., 2006).”
BackgroundMethodInfluentialSelf-citationTau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Self-citationTau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · cited 5×
“Initial reports have suggested this with demonstration of more widespread cortical AV-1451 uptake than initially predicted by Braak & Braak staging (Brier et al., 2016; Gordon et al., 2016; Johnson et al., 2009).”
BackgroundMethodResultInfluentialSelf-citationA framework for feature selection in clustering
Witten, D. M., & Tibshirani, R. (2010) · Journal of the American Statistical Association · doi:10.1198/jasa.2010.tm09415 · Cited by 696 · cited 1×
“We employed the sparse k-means (SKM) method (Witten and Tibshirani, 2010) to cluster our CN participants into two groups (k ¼ 2) denoting high and low levels of tau.”
MethodEarly clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 2×
“Early reports have shown a relationship between increased tracer uptake and worsening cognitive status (Brier et al., 2016; Chien et al., 2013; Day et al., 2017; Gordon et al., 2016; Johnson et al., 2015; Schöll et al., 2016; Wang et al., 2016)”
BackgroundMorris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603
Self-citationNeocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's Disease
Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K. L., & Perl, D. P. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540250089017 · Cited by 514
Schwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425 · cited 8×
“Involvement of the lateral occipital region is seen in prior work with AV-1451 (Brier et al., 2016; Gordon et al., 2016; Johnson et al., 2015; Schöll et al., 2016; Schwarz et al., 2016).”
BackgroundResultInfluentialVilleneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., et al. (2015) · Brain · doi:10.1093/brain/awv112 · Cited by 408
Partial volume correction in quantitative amyloid imaging
Su, Y., Blazey, T. M., Snyder, A. Z., Raichle, M. E., Marcus, D. S., Ances, B. M., Bateman, R. J., Cairns, N. J., Aldea, P., Cash, L., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.058 · Cited by 247
Self-citationQuantitative Analysis of PiB-PET with FreeSurfer ROIs
Su, Y., D'Angelo, G. M., Vlassenko, A. G., Zhou, G., Snyder, A. Z., Marcus, D. S., Blazey, T. M., Christensen, J. J., Vora, S., Morris, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073377 · Cited by 246
Self-citationGordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
Self-citationDuyckaerts, C., Brion, J. P., Hauw, J. J., & Flament-Durand, J. (1987) · Acta Neuropathologica · doi:10.1007/bf00693783 · Cited by 89 · cited 1×
“While increased β-amyloid deposition in the brain can be seen decades prior to symptom onset, both postmortem (Dela ere et al., 1989; Duyckaerts et al., 1987; McLean et al., 1999) and in vivo (Rowe et al., 2007; Villemagne et al., 2011) studies indicate that cross-sectional β-amyloid burden does…”
BackgroundNeuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology
Monsell, S. E., Mock, C., Hassenstab, J., Roe, C. M., Cairns, N. J., Morris, J. C., & Kukull, W. (2014) · Neurology · doi:10.1212/wnl.0000000000000650 · Cited by 71 · cited 1×
“Tests of memory and attention were selected as both have previously shown to be sensitive to preclinical levels of pathology (Aschenbrenner et al., 2015a, 2015b; Hassenstab et al., 2016; Monsell et al., 2014).”
Self-citation
Cited by
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Self-citationHigh-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Self-citationTau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Tau Kinetics in Neurons and the Human Central Nervous System
Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.015 · Cited by 586
Self-citationBarthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Detailed descriptions of imaging procedures in the BioFINDER-2 and Knight ADRC cohorts were previously reported 23,66,67 .”
MethodSelf-citation
Metadata
- Authors
- Mishra, S., Gordon, B. A., Su, Y., Christensen, J., Friedrichsen, K., Jackson, K., Hornbeck, R., Balota, D. A., Cairns, N. J., Morris, J. C., Ances, B. M., & Benzinger, T. L. S.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 161
- Pages
- 171-178
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2738088587
- Cited by
- 175
- References
- 26
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.